Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes

European Heart Journal: Acute Cardiovascular Care

Volumn 8, Issue 6, 2019, Pages 520-526

  Staudacher, Dawid L ^a   Putz, Vera ^a   Heger, Lukas ^a   Reinöhl, Jochen ^a   Hortmann, Marcus ^a   Zelenkofske, Steven L ^b   Becker, Richard C ^c   Rusconi, Christopher P ^b   Bode, Christoph ^a   Ahrens, Ingo ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Vitrisa Therapeutics Inc   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

acute coronary syndromes; anticoagulant reversal; Anticoagulation; factor IX; factor IXa; residual platelet reactivity

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANIVAMERSEN; BLOOD CLOTTING FACTOR 9A; CLOPIDOGREL; DUAL SPECIFICITY PHOSPHATASE 2; FIBRINOGEN RECEPTOR; PADGEM PROTEIN; PEGNIVACOGIN; PLACEBO;

ACUTE CORONARY SYNDROME; ANTIPLATELET ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; BLOOD CLOTTING TEST; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGHT TRANSMISSION AGGREGOMETRY; MULTIPLE ELECTRODE AGGREGOMETRY; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

EID: 85164548027     PISSN: 20488726     EISSN: 20488734     Source Type: Journal    
DOI: 10.1177/2048872617703065     Document Type: Article

References (29)

1. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med 2013; 368: 2004–2013.
2. Windecker S, Kolh P, Alfonso F,. 2014 ESC/EACTS Guidelines on myocardial revascularization: web addenda. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541–2619.
3. Amsterdam EA, Wenger NK, Brindis RG,. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130: e344–e426.
4. Ahrens I, Bode C. New parenteral anticoagulants: Focus on factor Xa and thrombin inhibitors. Curr Drug Discov Technol 2012; 9: 129–136.
5. Ahrens I, Bode C, Zirlik A. Anticoagulation during and after acute coronary syndrome. Hamostaseologie 2014; 34: 72–77.
6. Doktorova M, Motovska Z. Clinical review: Bleeding – a notable complication of treatment in patients with acute coronary syndromes: Incidence, predictors, classification, impact on prognosis, and management. Crit Care 2013; 17: 239.
7. Sofi F, Marcucci R, Gori AM,. Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events–a meta-analysis. Int J Cardiol 2008; 128: 166–171.
8. Parodi G, Marcucci R, Valenti R,. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 2011; 306: 1215–1223.
9. Tantry US, Bonello L, Aradi D,. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62: 2261–2273.
10. Brass LF. Thrombin and platelet activation. Chest 2003; 124: 18s–25s.
11. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258–264.
12. Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010; 104: 49–60.
13. Dyke CK, Steinhubl SR, Kleiman NS,. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: A phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 2006; 114: 2490–2497.
14. Tanaka KA, Szlam F, Rusconi CP,. In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry. Thromb Haemost 2009; 101: 827–833.
15. Catuogno S, Esposito CL, de Franciscis V. Developing aptamers by cell-based SELEX. Methods Mol Biol 2016; 1380: 33–46.
16. Rusconi CP, Roberts JD, Pitoc GA,. Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol 2004; 22: 1423–1428.
17. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987; 70: 307–315.
18. Ahrens I, Habersberger J, Baumlin N,. Measuring oxidative burden and predicting pharmacological response in coronary artery disease patients with a novel direct activator of haem-free/oxidised sGC. Atherosclerosis 2011; 218: 431–434.
19. Povsic TJ, Cohen MG, Mehran R,. A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trial. Am Heart J 2011; 161: 261–268. e1–2.
20. Ault KA, Cannon CP, Mitchell J,. Platelet activation in patients after an acute coronary syndrome: Results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1999; 33: 634–639.
21. Minnema MC, Peters RJ, de Winter R,. Activation of clotting factors XI and IX in patients with acute myocardial infarction. Arterioscler Thromb Vasc Biol 2000; 20: 2489–2493.
22. Povsic TJ, Vavalle JP, Alexander JH,. Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Results from the phase II RADAR-PCI study. EuroIntervention 2014; 10: 431–438.
23. Lincoff AM, Mehran R, Povsic TJ,. Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): A randomised clinical trial. Lancet 2016; 387: 349–356.
24. Bernlochner I, Mayer K, Orban M,. Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study. Platelets 2016: 1–9.
25. Zeymer U, Widimsky P, Danchin N,. P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: Use, patient selection, and outcomes from contemporary European registries. Eur Heart J Cardiovasc Pharmacother 2016: pvw005.
26. Moser M, Olivier CB, Bode C. Triple antithrombotic therapy in cardiac patients: More questions than answers. Eur Heart J 2014; 35: 216–223.
27. Gui T, Reheman A, Funkhouser WK,. In vivo response to vascular injury in the absence of factor IX: Examination in factor IX knockout mice. Thromb Res 2007; 121: 225–234.
28. Swieringa F, Kuijpers MJ, Lamers MM,. Rate-limiting roles of the tenase complex of factors VIII and IX in platelet procoagulant activity and formation of platelet-fibrin thrombi under flow. Haematologica 2015; 100: 748–756.
29. Podoplelova NA, Sveshnikova AN, Kotova YN,. Blood coagulation factors bound to procoagulant platelets are concentrated in their cap structures to promote clotting. Blood 2016; 128: 1745–1755.